Landmark FDA Action Requires New Warnings About NAION, a Serious Eye Condition That Can Cause Sudden and Permanent Vision Loss

PORT WASHINGTON, N.Y., Nov. 10, 2026 /PRNewswire/ -- Parker Waichman LLP, a national law firm representing individuals who have suffered serious injuries associated with prescription medications, today welcomed the U.S. Food and Drug Administration's decision requiring manufacturers of GLP-1 medications to add warnings concerning the potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a serious eye condition that can cause sudden and permanent vision loss.

The FDA's announcement applies to the entire class of GLP-1 receptor agonist medications, including Novo Nordisk's Ozempic, Wegovy, and Rybelsus, as well as Eli Lilly's Mounjaro and Zepbound. The agency is requiring manufacturers to include information concerning the potential increased risk of NAION in the Warnings and Precautions section of their prescribing information.

"This is an important development for millions of Americans who rely on these medications and deserve to be fully informed about their potential risks," said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP and Co-Chair of the Plaintiffs' Executive Committee in the federal GLP-1 NAION multidistrict litigation. "The FDA has now determined that the scientific evidence warrants an express warning about a condition that can cause permanent vision loss. Patients and their physicians should have this information when making decisions about treatment."

The FDA's decision represents a significant regulatory development concerning the safety of GLP-1 medications, which have become widely prescribed for diabetes and weight management. Unlike earlier international regulatory actions that focused primarily on semaglutide, the active ingredient in Ozempic and Wegovy, the FDA's announcement extends to the broader GLP-1 drug class, including medications manufactured by both Novo Nordisk and Eli Lilly.

NAION occurs when blood flow to the optic nerve is disrupted, potentially causing sudden, painless vision loss, typically in one eye. The resulting visual impairment can be permanent. For individuals who develop NAION, the consequences can be devastating, affecting their ability to work, drive, read, and perform ordinary activities of daily living.

Significance for Ongoing Federal Litigation

Parker Waichman LLP is actively involved in the federal multidistrict litigation involving GLP-1 medications and NAION, In re Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL No. 3163, pending before U.S. District Judge Karen S. Marston in the Eastern District of Pennsylvania.

The litigation involves allegations that certain GLP-1 medications can cause NAION and that manufacturers failed to adequately warn patients and healthcare providers about the potential risk of sudden and permanent vision loss.

The FDA's decision is particularly significant because the agency has now determined that the potential risk of NAION warrants an explicit warning in the prescribing information for these medications. The decision comes as litigation proceeds over whether manufacturers should have warned patients and healthcare providers about this risk earlier.

"For individuals who have already suffered permanent vision loss, today's announcement is especially meaningful," Goldstein added. "The central issue in these cases has always been whether patients and physicians were adequately warned about the risk of NAION. The FDA's decision underscores the importance of those warnings and raises serious questions about when manufacturers had sufficient information to alert the public to this potentially devastating injury."

The FDA's labeling action does not itself resolve the claims pending in the litigation, and the manufacturers dispute the allegations.

Parker Waichman LLP Is Accepting NAION Cases Nationwide

Parker Waichman LLP is currently accepting cases nationwide for individuals who have suffered sudden vision loss, blindness, or serious optic nerve damage after taking GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound.

Individuals who developed NAION or suffered permanent vision impairment after using these medications may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages.

Free Case Review for Affected Individuals

If you or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 medication, you may have a legal claim against the drug manufacturers.

Parker Waichman LLP is offering free, no-obligation case evaluations to help affected individuals understand their legal rights and options.

Contact Parker Waichman LLP Today

For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights.

About Parker Waichman LLP

Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. The firm has extensive experience representing individuals who have suffered serious eye injuries involving pharmaceutical products. Representative cases include In re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation and In re Bausch & Lomb Contact Lens Solutions Products Liability Litigation. With a proven track record of holding pharmaceutical companies accountable, the firm has secured billions of dollars in settlements and verdicts for injured clients.

Media Contact

Jason S. Goldstein, Esq.
Senior Litigation Counsel
Parker Waichman LLP
Phone: (516) 466-6500
Email: jgoldstein@yourlawyer.com
Website: www.yourlawyer.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/parker-waichman-llp-responds-to-fda-decision-requiring-vision-loss-warnings-for-ozempic-wegovy-mounjaro-zepbound-and-other-glp-1-drugs-302935168.html

SOURCE Parker Waichman LLP